about
The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation.Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents.Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluationDiscovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents.Recent advances in vascular disrupting agents in cancer therapy.A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation.Vascular disrupting activity of combretastatin analogues.Annexin 2A sustains glioblastoma cell dissemination and proliferation.A novel copper(I) complex induces ER-stress-mediated apoptosis and sensitizes B-acute lymphoblastic leukemia cells to chemotherapeutic agents.Synthesis and biological evaluation of imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyridines as new inhibitors of the Wnt/β-catenin signaling.Modeling and biological investigations of an unusual behavior of novel synthesized acridine-based polyamine ligands in the binding of double helix and G-quadruplex DNA.Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.Control of the DNA-Binding and Antiproliferative Properties of Hydroxybenzo[b]quinolizinium Derivatives with pH and Light.TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy.Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-AssembliesBMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastomaHIF-1α/Wnt signaling-dependent control of gene transcription regulates neuronal differentiation of glioblastoma stem cellsHuman Medulloblastoma Cell Lines: Investigating on Cancer Stem Cell-Like Phenotype
P50
Q27341833-FEEDCBDE-0035-432E-8AC6-FC30FD4BB1B9Q33560133-0CD091A1-4F78-424F-8202-E0204C557276Q34083310-DFB14164-6912-4170-909A-2A60A62A28A0Q36079759-A812A6F4-4F0E-4600-963F-610752238EF2Q38264533-FA88EC6B-5FDC-4C61-92D7-0F1E8854A2C9Q38689091-A04D0844-420B-4CFE-9FC4-3FAE3BCCDD53Q38767839-AD5C50A1-5980-416A-BE0D-0E27E01B0C40Q38840667-4EAAA9B3-ADB0-47EA-854C-C84B4455B5E2Q38979471-B1DC1FB3-F789-4A65-9390-A95F9AFCEBA0Q38982593-A7A46DC8-ACBA-4F11-A31D-D19E0BAAAFD6Q42854657-4935A2DF-3F83-4B9B-9176-F0429506DFB5Q47443074-41C7250C-85D2-4F69-A3B6-1489C9A1A99AQ48290499-A00FEBF0-E962-4064-9291-DF6B7163CD30Q49866304-D8F5C0A7-3422-4EED-92B1-B925252905D8Q57030083-00E1446C-2871-471E-8A16-F00B7C69802FQ57177045-55BF911E-4370-401B-AA0B-4C71DBA7F31CQ92604874-85C3BEF1-8389-4CE6-8D70-2E37B7FB30EEQ92811055-F9E05C5B-915F-4FFB-A467-511A855BB24E
P50
description
investigador
@es
researcher
@en
name
Elena Porcù
@en
type
label
Elena Porcù
@en
prefLabel
Elena Porcù
@en
P31
P496
0000-0003-1311-1079